Clinical Trial Update: Phase II Trial Evaluating Irinotecan and Capecitabine Relapsed/Refractory Upper GI Tumours [Phase 4]

View source ↗

Summary

The Phase II trial of irinotecan plus capecitabine for relapsed/refractory upper gastrointestinal tumours has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer
• Gastric Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• Irinotecan (Irinotecan)

Snippet

Sponsor: Royal Marsden NHS Foundation Trust | Conditions: Upper Gastrointestinal Tumours | Phase 4 | Status: COMPLETED